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Summary Forty patients with advanced breast cancer, randomised to receive CMF or weekly low dose
Epirubicin, were evaluated by UICC criteria of response and WHO toxicity criteria, in addition to three QoL
instruments: the 'Qualitator' daily diary card, 4 weekly Nottingham Health Profile (NHP) and Linear
Analogue Self-Assessment (LASA). Response rates were 58% for CMF and 29% for epirubicin (x2 = 3.51,
1 d.f., P>0.05). Median time to treatment failure was 24 weeks for CMF, 7 weeks for epirubicin (P<0.05)
but survival was similar in both groups. Survival was better for responders than for non-responders (medians
87 and 30 weeks, P=0.02). CMF caused more objective alopecia (P<0.001), nausea and vomiting (P<
0.001) and haematological toxicity (P<0.02). However, QoL measures only recorded a significant difference
in energy and pain, influenced primarily by the non-responders in each treatment group but with no difference
in overall global scores. Scores for responders, irrespective of treatment, were better to start with (LASA
P = 0.001); at 12 weeks, scores had improved (Qualitator P<0.05; NHP P<0.05). Scores in non-responders
showed no change. In this small study aggressive chemotherapy gave better response and similar survival
without impairing Quality of life overall. Detailed QoL measurement should be integral to all cancer
chemotherapy trials.
The treatment of patients with advanced breast cancer using
combination chemotherapy can cause significant toxicity
without greatly prolonging survival (Powles et al., 1980;
A'Hern et al., 1988). Recently, studies have been reported in
which low-toxicity regimens (single agent or short term) have
achieved palliation without affecting survival (Chlebowski et
al., 1989; Harris et al., 1990). For example, Jones has
reported a response rate of 43% with epirubicin given with a
weekly dose of approximately 20 mg. No significant myelo-
suppression, and minimal nausea and alopecia resulted
(Jones, 1988). Further studies have shown no improvement in
response rates by doubling the weekly dose from 20 to
40 mg. There was, however, a considerable increase in tox-
icity (Ebbs et al., 1989).
There is a danger that such low toxicity regimens may be
accepted without adequate comparison with conventional
combination cytotoxics. One of the most widely used regi-
mens in advanced breast cancer is the standard Cyclophos-
phamide, Methotrexate and 5-Fluorouracil (CMF) treatment
which achieves response rates of up to 60% (Bonadonna &
Van Oosterom, 1983). This was therefore chosen as the
control arm of a direct comparison with low-dose weekly
epirubicin. As reduced toxicity was central to the develop-
ment of the low-dose regimen, the trial was planned around
detailed measurement of Quality of Life.
Patients and methods
Patients
Between October 1988 and December 1989, 40 patients with
advanced breast cancer attending the Breast clinics at King's
College Hospital and the William Harvey Hospital were
randomised to receive CMF or epirubicin as first line chemo-
therapy. Criteria for inclusion were: histologically proven
locally advanced disease, rapidly progressing primary disease,
metastatic disease failing to respond to hormonal measures,
a first recurrence which was visceral, or recurrent disease
less than 2 years from primary treatment. Excluded, were
postmenopausal women with locally advanced disease
suitable for a trial of tamoxifen, those with a significant
medical condition or known previous or current cardiovas-
cular disease and patients who had received non-adjuvant
chemotherapy. The two groups were evenly matched accord-
ing to the sites of disease, and menopausal status, although
there was a difference in their median ages which was not
statistically significant (see Table I).
Ethical considerations
The trial was approved by the ethical committees in both
participating hospitals. Written informed consent was obtain-
ed from the patients prior to randomisation.
Treatment
All therapy was given in the outpatient clinic by one person.
The dose schedules were: (1) Epirubicin 20 mg intravenously,
given into fast-running 0.9% saline every 7 days; (2) Cyclo-
Table I Characteristics of patients entering study
Epirubicin CMF
Number
Median age
Premenopausal
Postmenopausal
Sites: soft tissues
Nodal
Lung
Liver
Bone
QoL medians and ranges
NHP
LASA
Qualitator
Scores on range of 0 10
NHP
LASA
Qualitator
21
52 (26-80)
9
12
10
9
6
6
9
129 (13-308)
54 (9-115)
64 (42-127)
2.2 (0.2-5.1)
2.5 (0.4-5.3)
2.8 (0.7-8.7)
19
63 (39-84)
4
15
10
12
6
6
9
91 (13-350)
35 (2-165)
75 (44-117)
1.5 (0.2-5.8)
1.6 (0.1-7.6)
3.8 (0.9-7.8)
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phosphamide 100 mg m2 orally on days 1-14, Methotrexate
35 mg m-2 intravenously on days 1 and 8 and 5-fluorouracil
600mg m- intravenously on days 1 and 8, on a 28 day
cycle.
Anti-emetics were given parenterally or orally as appropri-
ate. In practice, intravenous Metaclopramide 10 mg was
given prophylactically to every patient receiving CMF at the
time of cytotoxic administration and Prochloperazine in
tablet or suppository from was given on request to patients
to take at home. Dose reductions were made for patients
over 65 years old and dose modification made if the WBC
fell below 3000 16 or platelets to below 100 1-6. One patient
on CMF experienced mucositis for which she was given
Calcium Folinate 15 mg every 6 h for 24 h.
Assessment ofdisease
The endpoints chosen were: Time to treatment failure, sur-
vival, International Union Against Cancer (UICC) response
criteria, World Health Organisation (WHO) toxicity criteria
and Quality of Life. Time to treatment failure was defined as
the time to progression of lesions either on measurement or
symptomatically requiring addition to or alteration in ther-
apy, or the abandonment of treatment due to toxicity. If
treatment failure occurred before completion of a 6-month
course of treatment, alternative therapy was given as appro-
priate. After 6 months, chemotherapy ceased and no treat-
ment was given until or unless recurrence occurred or disease
progressed. Clinical and laboratory measurements made at
entry to study were a full medical history and examination,
weight, height, age, date of birth, PMH, full blood count,
differential WBC, biochemical screen. Photographs were
taken of visible lesions and records made of tumour dimen-
sions. All patients had a bone scan, liver ultrasound scan and
chest radiograph. CT scan was performed in patients whose
lesions were not otherwise measurable. Quality of life assess-
ment was made using the Nottingham Health Profile (Hunt
et al., 1985) and Linear Analogue SelfAssessment (Priestman
& Baum, 1976) at the start of treatment and four weekly
thereafter; throughout treatment, patients completed the
Qualitator daily diary card, a new instrument developed for
breast cancer chemotherapy trials (Fraser et al., 1990). Full
blood count was measured prior to administration of int-
ravenous cytotoxics. Patient characteristics were compared
using the Chi-squared and t-tests.
Survival and.response analysis
UICC criteria of response were assessed 4 weekly. The WHO
toxicity criteria were recorded every 4 weeks. UICC response
rates were compared using the Chi-squared test and time to
treatment failure and survival analyses were done using the
Kaplan-Meier life table method (Kaplan & Meier, 1958) and
log rank test (Peto et al., 1977). Correlation between initial
QoL scores and survival were done using Spearman's rank
correlation method.
Quality oflife analysis
With all instruments, a high score indicates poor QoL. The
NHP scores were analysed as recommended by the authors
so that at each completion, a weighted score out of a possible
100 was obtained for each of the six components: emotional
state, energy, pain, physical mobility, sleep and social factors.
In this study, the components were then added to give a
global score range of 0-600. The LASA questionnaire con-
sisted of 26 categories, each scored 0-9 on a visual analogue
scale. Two categories, the 'open' item and the general state-
ment on QoL were excluded from analysis, as the former was
ignored by most patients and the latter was judged to dup-
licate the rest of the questionnaire. The global range was
therefore 0-216. Both NHP and LASA were compared
between patient groups at each juncture using the Mann-
Whitney-U test. Comparison with subsequent scores was per-
formed using the Wilcoxon rank test. Completion of the
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Figure 1 Time to treatment failure (medians CMF 24 weeks,
Epirubicin 7 weeks, X2 = 5.17, 1 d.f., P<0.05, Epirubicin n = 21,
CMF n=19).
Qualitator involves the choice of five symptoms from a menu
of 23, in four domains, scoring on a categorical scale 1-4.
The details are described in the accompanying paper in this
issue; the range of the weekly global scores is from 35-140.
For comparison, pre-treatment NHP and LASA scores were
compared with the first week of the Qualitator and there-
after, the comparison of NHP and LASA 4 weekly scores
was with an average of each patient's aggregated Qualitator
scores for that period. Analysis was then performed using the
same non-parametric methods as for the NHP and LASA.
Analysis of individual Qualitator symptoms is also described
in the accompanying paper.
Exclusions
Forty patients were entered into the trial. Thirty-seven
patients completed the NHP and 36 the LASA at the start of
the study. Three exclusions were patients who were unable to
start treatment following randomisation and subsequently
left the study. The other LASA was incorrectly completed by
the fourth patient. Thereafter, patients remaining in the study
completed the NHP and LASA during each month of treat-
ment. Three CMF patients failed to do so at I month and
one at 5 months; one patient failed to complete them at 4
months. The Qualitator was commenced by 29 patients. At
the start of the study three elderly patients were, in retrospect
mistakenly, not offered the Qualitator. One patient, once
randomised refused to complete it, one progressed rapidly
after 1 month and was unable to return the card. The
remaining six patients progressed rapidly within a week of
the start of treatment and were also unable to return the
diary cards.
Results
UICC response
The response rates according to UICC criteria were 58% for
the CMF group and 29% for the Epirubicin group (x2 =
3.51, 1 d.f., P>0.05, see Table II). If the six patients who
relapsed before or within the first week of treatment are
Table II Response by randomisation
UICC response CMF Epirubicin
Complete I 0
Partial 10 6
No change 2 7
Progression 3 5
Rapid progression 3 3
x2= 3.510, 1 d.f., P>0.05. Excluding 3 in each group with rapidly progressive disease, x2 = 4.300, 1 d.f., P<0.05.404 S.C.A. FRASER et al.
excluded as in other studies the difference is significant
(X2=4.30, 1 d.f., P<0.05).
The time to treatment failure was longer for CMF patients
than epirubicin patients: median 24 weeks and 7 weeks
(X2 = 5.17, 1 d.f., P<0.05, see Figure 1).
Survival
Survival was similar in both treatment groups: medians 57
weeks and 55 weeks respectively (X2 = 1.38; 1 d.f., P= 0.24)
(see Figure 2). UICC responders, as expected from many
previous studies (A'Hern et al., 1988) survived longer than
that non-responders: medians 87 weeks and 30 weeks (x2=
5.42, 1 d.f., P<0.05, see Figure 3).
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Figure 2 Overall survival (medians CMF 57 weeks, Epirubicin
55 weeks, x2 = 1.38, 1 d.f., P = 0.24, Epirubicin n = 21, CMF
n= 19).
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Figure 3 Overall survival according to UICC response (medians
responders 87 weeks, non-responders 30 weeks, x2= 5.42, 1 d.f.,
P = 0.02, response n = 17, no response n = 23).
Table III Toxicity by WHO grade: number (%) of each treatment
group in each category, on each month of treatment
WHO Nausea or
Rx Total grade Alopecia vomiting Haematological
Epi 83 0 75 (90) 83 (100) 82 (99)
1 8(10) 0 0
2 0 0 0
3/4 0 0 1 (1)
CMF 106 0 43 (41) 64 (60) 75 (71)
1 20 (19) 22 (21) 20 (19)
2 12 (11) 10 (9) 7 (7)
3/4 31 (29) 10 (9) 4 (4)
P<0.001 P<0.001 P<0.02
Toxicity
Toxicity was very low for all patients receiving epirubicin.
CMF caused significantly more alopecia (P<0.001), nausea
and vomiting (P<0.001) and haematological toxicity (P<
0.02) above WHO grade I (see Table III). One CMF patient
required hospital admission for treatment of septicaemia.
One epirubicin patient receiving prednisolone for scleroderma
developed septicaemia requiring hospital admission. There
were no fatalities due to side-effects of treatment.
Quality oflife at entry to the trial
The respective NHP, LASA and equivalent aggregated week-
ly Qualitator scores were compared for each 4 weeks.
Patients' QoL scores were analysed according to response
and to treatment. Prior to the start of treatment, a poorer
QoL was recorded amongst patients who subsequently did
not respond, statistically significant only for the LASA,
(P<0.002). The pre-treatment scores are illustrated in Figure
4, in which the LASA, NHP and Qualitator scores are
standardised to a scale of 0-10.
Patients' QoL scores at the start of the study were cor-
related by rank with their subsequent survival. The Spearman
co-efficients were -0.52 (95% c.i., -0.72, -0.23) for the
LASA, -0.35 (-0.60, 0.04) for the NHP, -0.64 (-0.82,
-0.36) for the Qualitator.
Quality oflife during treatment
Compliance for the 29 patients who started the Qualitator,
the 37 who started the NHP and 36 who started the LASA
respectively were 88%, 89% and 92%. Figure 5 shows the
mean global QoL values in each treatment group at each
stage for all patients remaining in the study. The means are
used purely for graphic representation: statistical comparison
between treatment groups was by a rank test at each 4 weeks.
By 3 months, the scores of patients with a UICC response
in both the epirubicin and CMF treatment groups had im-
proved significantly in the Qualitator (medians 60.5 to 48,
P<0.05) and NHP (medians 83 to 24, P<0.05) though not
in the LASA (medians 22 to 29) scores (see Figures 6a to 6c).
Nonresponders experienced no significant difference in their
initial scores and the final scores prior to treatment failure:
Qualitator medians 80 to 74 (P = 0.5), NHP medians 133 to
182 (P= 0.435), LASA medians 64 to 71 (P = 0.55). The
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Figure 4 Standardised QoL scores at start of treatment accord-
ing to subsequent response: Qual = Qualitator, NHP = Notting-
ham Health Profile, LASA = Linear Analogue Self-Assessment,
Res = Response, No R = No Response.
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Figure 5 Standardised mean QoL scores at each month of treat-
ment for Epirubicin patients and CMF patients .
pretreatment difference in scores between responders and
non-responders persisted on each monthly comparison: one
month (LASA P<0.02, NHP P<0.01, Qualitator P<0.05),
2 months (Qualitator P<0.05), 3 months (NHP P<0.05,
Qualitator P<0.01) and 4 months (NHP P<0.05).
All of the QoL measures allow sub-analysis in considerable
detail. In separate analysis of the six domains of the NHP
(emotional state, energy, pain, physical mobility, sleep and
social factors) and the LASA and Qualitator symptoms in
four sub-groups (physical symptoms, social factors, emo-
tional factors and physical performance), non-responders had
worse scores at most stages (see accompanying paper in this
issue). The only significant difference between treatment
groups was a better score in CMF than Epirubicin patients in
the NHP score for pain at 2 months (median differences 0
and 9.5, P<0.05), energy at 3 months (medians 0 and 24,
P<0.05) and a worse Qualitator score at 3 months for
personal relationships in CMF patients (median 7 and 7.65,
P<0.05). In each case the high scores were amongst the
non-responders in each group.
Discussion
One of the most difficult decisions facing clinicians treating
patients with advanced breast cancer is what to do when
second line hormone therapy fails. At what point does one
advise chemotherapy, to whom and how aggressively? Until
recent years, the success of a treatment regimen has been
defined almost solely by tumour shrinkage. Although toxic
side effects have been measured, there was little evidence of
correlation with the patient's experience. The failure of many
studies to show a survival advantage to any regimen caused
some clinicians to question the merits ofgiving chemotherapy
at all (Powles et al., 1980). During the last decades, the
concept of Quality of Life has become increasingly important
in those patients in whom little survival advantage is
anticipated through treatment and efforts were made to de-
fine and measure it (Fallowfield, 1990). Increasing numbers,
but still a minority, of studies measure QoL (Bryne, 1992).
The disparate instruments and periods of measurement have
made it difficult to interpret how chemotherapy affects QoL
for patients with advanced breast cancer. The aim of this
study was to compare a standard combination regimen with
a single agent regimen in which different toxicity and possibly
different response rates could be anticipated, and whether a
difference in survival or QoL would result. Detailed intermit-
tent QoL measurement was made with three instruments, two
of which were specifically designed for the task. The response
data were consistent with previous studies in that the patients
who had a measurable response enjoyed longer overall sur-
vival. Although survival among patients with non-progressive
disease was better for CMF patients, the poor survival of
CMF non-responders was enough to redress this balance so
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Figure 6 a,b,c: Standardised QoL scores in patients who res-
ponded, at I week and 12 weeks for the Qualitator (15 patients),
before treatment and at 3 months for the Nottingham Health
Profile (17 patients) and Linear Analogue Self-Assessment (17
patients).
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that survival for the two treatment groups as a whole was
equal. Few studies are large enough to show a survival
difference between treatment groups, but A'Hern et al. show-
ed that a better response rate equated with longer median
survival in a statistical overview of 50 chemotherapy trials
(A'Hern et al., 1988). The QoL data were not wholly
expected. Although Ebbs et al. (1988) had reported that good
pre-treatment QoL scores were associated with a subsequent
response, we found that there was a close correlation with
subsequent duration of survival too. Morris and Sherwood
(1987) described this in terminally ill patients, and Adding-
ton-Hall et al. (1990) used the Spitzer QoL Index (Spitzer et
al., 1981) to predict duration of survival in 230 terminally ill
patients. However, it was a surprise that even in this small
study, such a consistent trend would emerge. In the context
of patients with advanced breast cancer, this may be of
significance in deciding on treatment.
Low objective toxicity in patients treated with epirubicin
was reflected in the recording of specific treatment-related
symptoms in the Qualitator, but QoL scores overall were
unaffected and resembled closely the global scores of the
other two instruments.
Is a harsher regimen therefore the treatment of choice for
advanced breast cancer? The evidence is that it does not
impair QoL in non-responders of whom there are fewer
anyway and QoL improves for responders, as previously
reported by Baum et al. (1980). Coates et al. (1987) found
that Quality of Life declined significantly in patients on a less
aggressive regimen in which response was poorer and Slevin
et al. (1990) found cancer patients much more willing to
comtemplate radical chemotherapy than were their doctors
for them. However, if pre-treatment QoL scores give not only
a guide to response, but to survival as well, then perhaps
those patients with clinically advanced disease in whom QoL
is poor, who will not respond and whose survival will be
poor should not be given chemotherapy at all. A different
interpretation might be that those patients whose disease is
not yet advanced enough to affect their QoL are those most
likely to respond to treatment. In a recent study, patients
with metastatic cancer of bowel, lung, pancreas or mela-
noma, who received conventional therapy, including chemo-
therapy, had no better survival than matched controls having
'alternative' therapy. Chemotherapy was not associated with
a worse QoL, and although the change in QoL was similar in
both groups, the patients treated conventionally started and
finished with better QoL measurement. This may have been
influenced by the social composition of the groups: a higher
number of alternative therapy patients had degrees and poor
QoL may have contributed to their decision to seek un-
proven therapy. The ideal study in such patients would be
randomised, with an arm involving palliative care only (Cas-
sileth et al., 1991).
One way of resolving the difficulty would be to involve the
patient more fully in the decision-making process. This app-
roach was recently advocated in early breast cancer treatment
by Wennberg and colleagues who have used interactive
videotapes (Wall Street Journal, 1992).
The present study does not provide solutions to these
uncertainties. However, detailed QoL measurement is shown
to add valuable and perhaps not wholly expected information
in evaluating advanced breast cancer chemotherapy. QoL
measurement may be of use in defining individual strategies.
Only by including QoL measurement in more protocols will
knowledge of its precise role become clear.
We are most grateful to Farmitalia Carlo Erba for the financial and
technical support which enabled this study to proceed.
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